Management of Anti‐drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease
Open Access
- 1 November 2019
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 69 (5) , 551-556
Abstract
Background: Treatment of pediatric inflammatory bowel disease (IBD) with monoclonal anti‐ tumor necrosis factor‐alpha (TNFα) can result in immunogenicity and formation of anti‐drug antibodies (ADAs). ADAs are associated with loss of clinical response and worsening disease progression. Data examining treatment interventions to overcome ADA in pediatric patients with IBD are lacking.Results: Medical records were reviewed from 234 children and adolescents with IBD treated with infliximab or adalimumab who underwent therapeutic drug monitoring (626 tests). All patients who had detectable antibodies were further analyzed. A total 58 patients (24.8%) developed ADA while being treated with infliximab or adalimumab. The incidence of antibody development was 12.9 per 100 person‐years of anti‐TNF treatment. Twenty‐eight patients underwent dose optimization and 54% had undetectable ADA on follow‐up monitoring. The mean duration of antibody suppression was 16.8 ± 10.9 months in those who were successfully suppressed with optimization. Patients who switched to a second anti‐TNF medication were not more likely to develop antibodies to the second agent.Conclusions: With limited therapies for IBD and the chronicity of the disease, we advocate salvage of the current anti‐TNF through dose optimization in pediatric patients with antibody level <10 U/mL.Keywords
This publication has 18 references indexed in Scilit:
- Cancer and Immunomodulators in Inflammatory Bowel DiseasesInflammatory Bowel Diseases, 2015
- Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBDInflammatory Bowel Diseases, 2015
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's DiseaseGastroenterology, 2014
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2012
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2012
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut, 2009
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003